IN THE UNITED STATES PATENT AND TRADEMARK OFFICE Examiner: Dong Jiang Ellen FILVAROFF, et al. Application Serial No. 10/617,573 Filed: July 11, 2003 For: PHARMACEUTICAL COMPOSITIONS, KITS, AND THERAPEUTIC USES OF PATENT AND TRADEMARK OFFICE Examiner: Dong Jiang Confirmation No: 8245 Confirmation No: 8245 Customer No. 77845

EXPRESS MAIL LABEL NO. EM 303 999 068 US DATE MAILED: OCTOBER 19, 2009

ANTAGONIST ANTIBODIES TO IL-17E

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97

MAIL STOP RCE

Commissioner for Patents PO Box 1450 Alexandria, Virginia 22313-1450

Sir:

Listed below or on an attached Form PTO-1449 is information known to applicant(s). A copy of each listed publication and U.S. and foreign patent, except for pending U.S. applications, is being submitted herewith, along with a concise explanation of information in a foreign language, if any, pursuant to 37 C.F.R. §1.97-1.98.

Applicants respectfully request that the listed information be considered by the Examiner and be made of record in the above-identified application. If Form PTO-1449 is enclosed, the Examiner is requested to initial and return it in accordance with M.P.E.P. §609.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, material to patentability as defined in §1.56.

\bowtie	This statement qualifies under 37 C.F.R. §1.97, subsection (b) because (check all that apply)			
		(1) It is being filed within 3 months of the application filing date and is other than a continued prosecution application under § 1.53(d) OR		
		(2) It is being filed within 3 months of entry of a national stage OR		
		(3) It is being filed before the mail date of the first Office Action on the merits OR		
		(4) It is being filed before the mailing of a first Office Action after the filing of a request for continued examination under § 1.114.		
	filing d stage as action of	37 C.F.R. §1.97(c). If this statement is being filed after the latest of: (1) three months beyond the filing date of a national application; (2) three months beyond the date of entry of the national stage as set forth in §1.491 in an international application; or (3) the mailing date of a first Office action on the merits, but before the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, then:		
		a certification as specified in §1.97(e) is provided below; or		
		a fee of \$180.00 as set forth in \$1.17(p) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.		
	office a	37 C.F.R. $\S1.97(d)$. If this statement is being filed after the mailing date of the earlier of a final office action under $\S1.113$ or a notice of allowance under $\S1.311$, but before payment of the issue fee, then:		
	A.	a certification as specified in §1.97(e) is completed below; and		
	В.	a petition under 37 C.F.R. §1.97(d) requesting consideration of this statement is submitted herewith; and		
	C.	a fee of \$130.00 as set forth in §1.17(i)(1) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.		
	of \$0.0	Authorization. The Commissioner is hereby authorized to charge the above-referenced fees 0.00 and any additional fees or credit any overpayment associated with this communication to losit Account No. 50-4634 (Attorney's Docket No. GNE-0290.041 / 123851-181748).		
		Respectfully submitted,		
Dated: October 19, 2009 By:				
Goodwin Procter LLP 135 Commonwealth Drive Menlo Park, California 94025 Telephone: (650) 752-3100 Facsimile: (650) 853-1038				